As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

The new indication puts Augtyro in contention with other therapies for NTRK gene fusion cancers, including Rozlytrek (entrectinib) and Bayer’s Vitrakvi (larotrectinib), which were approved for ...

Rozlytrek was approved by the FDA in the NTRK indication in August last year, following on from a first approval in Japan in June last year. Bayer’s Vitrakvi (larotrectinib) was approved in the ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...